Dewpoint receives FDA orphan drug designation for DPTX3186
The ODD programme incentivises the development of medicines for conditions affecting fewer than 200,000 individuals in the US.
Cancer
FDA approves Lilly’s Inluriyo to treat advanced breast cancer
FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA
Akeso gains NMPA approval for cadonilimab to treat cervical cancer
ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study
Epsilogen acquires TigaTx to expand pan-isotope cancer antibody pipeline
NICE green lights two blood cancer therapies for NHS use
World Cancer Day: WHO warns of rising cancer burden in Southeast Asia
